Results 81 to 90 of about 1,518 (207)

New Topical and Systemic Treatments for Atopic Dermatitis

Clinical &Experimental Allergy, Volume 55, Issue 11, Page 1057-1069, November 2025.
This review summarises new topical and systemic treatments for atopic dermatitis, their relative effectiveness, and important safety data. ABSTRACT Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course.
Sara Mirali, Aaron M. Drucker
wiley   +1 more source

Italian Guidelines in diagnosis and treatment of alopecia areata [PDF]

, 2019
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy.
Alessandrini, Aurora, Amendolagine, Graziana, Annunziata, Maria Carmela, Arisi, Maria Chiara, Astorino, Stefano, Babino, Graziella, Bardazzi, Federico, Barruscotti, Stefania, Belloni Fortina, Anna, Borghi, Alessandro, Bruni, Francesca, Caccavale, Stefano, Calvieri, Stefano, Calzavara-Pinton, Piergiacomo, Cameli, Norma, Cardone, Michele, Carlesimo, Marta, Caro, Gemma, Carugno, Andrea, Coppola, Rosa, D\u2019Arino, Andrea, D\u2019Ovidio, Roberto, Dattola, Annunziata, De Felici Del Giudice, Maria Beatrice, Di Cesare, Antonella, Di Nunno, Donato, Dika, Emi, Fabbrocini, Gabriella, Federico, Alessandro, Feliciani, Claudio, Fortuna, Maria Caterina, Fulgione, Elisabetta, Galluzzo, Marco, Garcovich, Simone, Garelli, Valentina, Guerriero, Cristina, Hansel, Katharina, La Placa, Michelangelo, Lacarrubba, Francesco, Lora, Viviana, Magri, Francesca, Mandel, Victor Desmond, Marinello, Elena, Megna, Matteo, Micali, Giuseppe, Misciali, Cosimo, Monari, Paola, Monfrecola, Giuseppe, Muscianese, Marta, Neri, Iria, Offidani, Annamaria, Orlando, Gloria, Papini, Manuela, Patrizi, Annalisa, Piaserico, Stefano, Pigliacelli, Flavia, Piraccini, Bianca Maria, Rivetti, Niccol\uf2, Rossi, Alfredo, Simonetti, Oriana, Stan, Teodora Roxana, Starace, Michela, Stingeni, Luca, Talamonti, Marina, Tassone, Francesco, Villa, Lucia, Vincenzi, Colombina   +66 more
core   +2 more sources

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report

Journal of Dermatological Treatment
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event ...
Camille M. Powers, Hannah Verma, Jeremy Orloff, Austin J. Piontkowski, Amy Tiersten, Angela Lamb, Nicholas Gulati   +6 more
doaj   +1 more source

Sclerosing diseases of the skin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 10, Page 1282-1301, October 2025.
Summary Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients’ quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality.
Yasamin Kalantari, Katharina Meier, Kamran Ghoreschi, Maria Kinberger, Farzan Solimani   +4 more
wiley   +1 more source

A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing [PDF]

, 2019
Background: Cutaneous squamous cell carcinoma (cSCC) incidence continues to rise with increasing morbidity and mortality, with limited treatment options for advanced disease.
Ai Nagano, Bengtsson, Catherine A. Harwood, Celine Pourreyron, Charlotte M. Proby, Dimitris Athineos, Gareth J. Inman, Irene M. Leigh, Jun Wang, Karen Blyth, Karin J. Purdie, Matthew Caley, Moore, Nikol Mladkova, Purdie, Sakinah Hassan, Sandeep Dhayade, Viviana Mannella   +17 more
core   +4 more sources

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

A Scoping Review of Pathogenesis, Current Treatments, and Novel Approaches for Vitiligo

Journal of Cosmetic Dermatology, Volume 24, Issue 10, October 2025.
ABSTRACT Background Vitiligo is a chronic skin disorder characterized by loss of melanocytes, causing depigmentation and psychological distress. Its pathogenesis is complex and multifactorial, involving genetic predisposition, autoimmune, oxidative stress, and neurogenic mechanisms.
Nusaibah Sallehuddin, Nur Izzah Md Fadilah, Mh Busra Fauzi, Manira Maarof   +3 more
wiley   +1 more source

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023

Diseases
Vitiligo, an autoimmune disorder causing depigmented skin patches, includes two types, segmental (SV) and non-segmental (NSV). Previously, NSV was off-label treated using Calcineurine inhibitors (Tacrolimus and Pimecrolimus).
Saleh F. Alqifari, Musaab Habibulla Gari, Jeff J. Guo, Shoroq Alamin, Aya K. Esmail, Abdullah K. Esmail, Heba R. Hamad, Ahmed Aljabri, Amirah M. Alatawi, Laila A. Albishi, Mohammed Olaythah Alraddadi, Helal F. Hetta   +11 more
doaj   +1 more source

Risks of topical corticosteroid therapy and role for advanced targeted topical treatments for inflammatory skin diseases: an expert consensus panel [PDF]

Topical corticosteroids are a first-line therapy for inflammatory skin diseases and are commonly used for chronic management. Topical corticosteroids can lead to cutaneous and systemic adverse events.
Burshtein, Joshua, Chovatiya, Raj, Golant, Alexandra, Lebwohl, Mark, Lio, Peter, Shah, Milaan, Zakria, Danny   +6 more
core   +1 more source

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream [PDF]

, 2020
BACKGROUND: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.
Howell, Michael D, INCB 18424-206 Study Investigators,, Kim, Brian S, Kuligowski, Michael E, Nasir, Adnan, Papp, Kim, Sun, Kang   +6 more
core   +1 more source